Free Trial

IM Cannabis Q2 2023 Earnings Report

IM Cannabis logo
$1.59 +0.08 (+5.30%)
As of 02:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IM Cannabis EPS Results

Actual EPS
-$1.14
Consensus EPS
-$0.78
Beat/Miss
Missed by -$0.36
One Year Ago EPS
N/A

IM Cannabis Revenue Results

Actual Revenue
$9.83 million
Expected Revenue
$10.17 million
Beat/Miss
Missed by -$340.00 thousand
YoY Revenue Growth
N/A

IM Cannabis Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

IM Cannabis Earnings Headlines

IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
IM Cannabis (IMCC) Projected to Post Quarterly Earnings on Monday
IM Cannabis Announces Change of Auditors
See More IM Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email.

About IM Cannabis

IM Cannabis (NASDAQ:IMCC) engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

View IM Cannabis Profile

More Earnings Resources from MarketBeat